Sage Journals: Discover world-class research

Abstract

OBJECTIVE:

Selfheal has been used for many years in hyperprolactinemia induced galactorrhea, menstrual disorders, and dysgenesis with satisfactory curative effect. However, its mechanism is still unclear. This study intended to investigate the effect of selfheal extract on hyperprolactinemia in vivo and in vitro, in order to elucidate its mechanism of anti-hyperprolactinemia.

PATIENTS AND METHODS:

Hyperprolactinemia rat model was established. High dose (28.8 g/(kg $\cdot$ d)), middle dose (14.4 g/ (kg $\cdot$ d)), and low dose (7.2 g/(kg $\cdot$ d)) of selfheal extract were used to treat the model to observe impact on serum estradiol (E2), progesterone (P), prolactin (PRL), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels. Three cell lines MMQ, GH3, and PC12 were applied to investigate selfheal extract effect on PRL secretion, dopamine D2 receptor, and dopamine transporter (DAT).

RESULTS:

High and middle dose of selfheal extract significantly reduced PRL level in hyperprolactinemia rat compared with model group ( $P<$ 0.01). Compared with normal control, 5 mg/ml and 10 mg/ml selfheal extract obviously inhibited PRL secretion in MMQ cells that high expressed D2 receptor after 24 hours ( $P<$ 0.01), but did not affect PRL secretion in GH3 cells lack of D2 receptor. 8 mg/ml selfheal extract markedly suppressed D2 receptor and DAT expression in PC12 cells that strongly expressed D2 receptor and DAT ( $P<$ 0.01).

CONCLUSIONS:

Selfheal extract treated hyperprolactinemia through dopamine D2 receptor with significant effect.

Keywords

Selfheal extract hyperprolactinemia PRL dopamine D2 receptor DAT

Get full access to this article

View all access options for this article.

References

Lee

D.Y.

Y.K.

Yoon

B.K.

and Choi

, Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems, Am J Obstet Gynecol 206 (2012), 213 e211–215.

Pacchiarotti

Murru

Kotzalidis

G.D.

Bonnin

C.M.

Mazzarini

Colom

and Vieta

, Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice, Eur Neuropsychopharmacol 25 (2015), 1045–1059.

Ranjbar

Sadeghi-Bazargani

Niari Khams

Arfaie

Salari

and Farahbakhsh

, Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia, Neuropsychiatr Dis Treat 11 (2015), 549–555.

Shibli-Rahhal

and Schlechte

, Hyperprolactinemia and infertility, Endocrinol Metab Clin North Am 40 (2011), 837–846.

Mah

P.M.

and Webster

, Hyperprolactinemia: etiology, diagnosis, and management, Semin Reprod Med 20 (2002), 365–374.

Webster

Piscitelli

Polli

Ferrari

C.I.

Ismail

and Scanlon

M.F.

, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea, Cabergoline Comparative Study Group, N Engl J Med 331 (1994), 904–909.

Wang

Chen

Y.G.

Z.H.

J.Y.

Liu

X.G.

Zou

J.L.

and Wu

J.H.

, Effect of Chinese medical herbs-Huiru Yizeng Yihao on hyperprolactinemia and hyperplasia of mammary gland in mice, Afr J Tradit Complement Altern Med 10 (2013), 24–35.

Lin

K.C.

Kawamura

Okamura

and Mori

, Inhibition of ovulation,steroidogenesis and collagenolytic activity in rabbitts by sulpiride-induced hyperprolactinemia, Reprod Fert 83 (1988), 612.

Shi

X.-Q.

, Modern medical laboratory animal science, ed. Beijing: People’s Medical Publishing House, 2000.

10.

Asa

S.L.

and Ezzat

, The pathogenesis of pituitary tumours, Nat Rev Cancer 2 (2002), 836–849.

11.

Freeman

M.E.

Kanyicska

Lerant

and Nagy

, Prolactin: structure, function, and regulation of secretion, Physiol Rev 80 (2000), 1523–1631.

12.

Muranyi

Gergely

Fekete

M.I.

and Nagy

G.M.

, Protein phosphatase 2A plays a role in the suckling-induced changes in the responsiveness of pituitary mammotropes, Endocrinology 139 (1998), 4590–4597.

13.

Diamond

S.E.

Chiono

and Gutierrez-Hartmann

, Reconstitution of the protein kinase A response of the rat prolactin promoter: differential effects of distinct Pit-1 isoforms and functional interaction with Oct-1, Mol Endocrinol 13 (1999), 228–238.

14.

Brooks

C.L.

, Molecular mechanisms of prolactin and its receptor, Endocr Rev 33 (2012), 504–525.

15.

Araujo

A.S.

Simoes Mde

Verna

Simoes

R.S.

Soares Junior

J.M.

Baracat

E.C.

and Gomes

R.C.

, Influence of hyperprolactinemia on collagen fibers in the lacrimal gland of female mice, Clinics (Sao Paulo) 70 (2015), 632–637.

16.

Fitzgerald

and Dinan

T.G.

, Prolactin and dopamine: what is the connection? A review article, J Psychopharmacol 22 (2008), 12–19.

17.

Huan

Cui

and Ren

, The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients, Pak J Pharm Sci 28 (2015), 713–718.

18.

Krishna

Ganiger

Kannan

Gopalakrishnan

and Goel

, Reversibility of dopamine receptor antagonist-induced hyperprolactinemia and associated histological changes in Tg RasH2 wild-type mice, Reprod Toxicol 58 (2015), 73–78.

19.

Zhao

R.R.

Fennell

W.H.

and Abel

F.L.

, Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics, Eur J Pharmacol 190 (1990), 193–202.

20.

Salama

Lober

Hubner

and Gmeiner

, Synthesis and binding profile of haloperidol-based bivalent ligands targeting dopamine D(2)-like receptors, Bioorg Med Chem Lett 24 (2014), 3753–3756.

The mechanism of selfheal extract in treating hyperprolactinemia